Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : UBS Adjusts Johnson & Johnson's Price Target to $183 From $180; Neutral Rating Kept

07/23/2021 | 09:52am EDT


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
03:11pThree US Opioid Distributors Settle Opioid-Related Claims With Cherokee Nation
MT
02:03pMODERNA : CDC finds reactions to booster dose of COVID-19 vaccine similar to second
AQ
11:22aJOHNSON & JOHNSON : Two Pioneering RNA Scientists Win the 2021 Dr. Paul Janssen Award for ..
PU
08:52aARROWHEAD PHARMACEUTICALS : Earns $10 Million Phase 1 Milestone Payment, Based on Agreemen..
MT
08:25aJOHNSON & JOHNSON : - New Phase 3 Data Suggest Positive Effect and Show Similar Safety wit..
AQ
08:25aJOHNSON & JOHNSON : John Sisk & Son - Bio Cork 2 named 'International Project of the Year ..
AQ
08:11aJOHNSON & JOHNSON : The Janssen Pharmaceutical - New Phase 3 Data Suggest Positive Effect ..
AQ
07:52aJOHNSON & JOHNSON : Launches a Health Equity Innovation Challenge in 6 U.S. Cities
PU
07:01aJOHNSON & JOHNSON : Celebrates COVID-19 Vaccine Science Superheroes
PR
09/27JOHNSON & JOHNSON : New Phase 3 Data Suggest Positive Effect and Show Similar Safety with ..
PU
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 029 M - -
Net income 2021 22 809 M - -
Net Debt 2021 593 M - -
P/E ratio 2021 18,9x
Yield 2021 2,56%
Capitalization 429 B 429 B -
EV / Sales 2021 4,56x
EV / Sales 2022 4,35x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 162,81 $
Average target price 185,83 $
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.45%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.18.36%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY31.25%205 250
ABBVIE INC.0.18%190 360